With 250 new drug approvals in its historical past, Calyx has supported over 25,000 trials involving greater than fourteen million sufferers. The corporate will proceed its give attention to offering revolutionary know-how options and companies to hurry the invention of latest remedies.
“In the present day our trade wants to maneuver at a 21st century tempo and Calyx, as an impartial firm, is concentrated on enabling world biopharmaceutical prospects and medical analysis organizations (CROs) to leverage revolutionary know-how options and companies within the pursuit of cures,” mentioned Gavin Nichols, Chief Govt Officer at Calyx. “Whereas the identify is new, Calyx has a protracted historical past of fixing complicated issues to speed up new product improvement – from deciding on the correct biomarker in early stage imaging to the digital administration of whole world improvement applications. We’re enthusiastic about this subsequent stage of our journey.”
Calyx will stay privately held by the identical possession group that has owned and invested in Parexel since 2017.
Be taught extra at calyx.ai
By revolutionary eClinical options and companies, Calyx turns the unsure into the dependable, serving to carry new medical remedies to market quicker. With deep experience in medical improvement and greater than 25 years of supporting trial sponsors and medical analysis organizations (CROs), Calyx harnesses that intelligence and prompts its potential to unravel complicated issues, ship quick insights, and get new medicine to market day-after-day.
Medical Imaging | IRT | CTMS | EDC | RIM
CONTACT: Christine Tobin | +1412-628-8598 | email@example.com